Submit Sample

CADET BRAF

BRAF mutation test is a diagnostic molecular biomarker of canine transitional cell carcinoma (TCC), urothelial Carcinoma (UC) and prostate gland carcinoma (PC).  Although, the gold standard way for the diagnosis of UC and PC is cytology or histopathological evaluation of the tissue usually through a biopsy. But, obtaining a biopsy sample is always challenging and risky because of its invasive nature and potential seeding of tumour cells. Often, the cytological and histopathological findings can be inconclusive due to the marked pleomorphism and masking of the tumour cells by severe inflammatory cells and artifacts. The aggressiveness of these tumors result from delayed diagnosis and therapeutic intervention. BRAF mutation testing is a highly specific method (100%) for the detection of TCC, UC and PC. Research showed that the mutation was detected in 85% of confirmed cases of canine TCC. Thus, CADET BRAF mutation test provides a non-invasive detection of TCC and PC. The test mutation is not suitable for the diagnosis in cats.

Test name

CADET BRAF

Test Code

1001

Section

Cancer Diagnostics

Species

Canine

Specimen

Urine

Sample Container

Specific urine collection container

Turnaround time

14-21 days

Collection Guidelines

40 ml of only free catch urine is to be collected and transferred immediately in the specific urine container having preservatives. The urine sample can be collected over 3 days. The urine sample is stable at room temperature for several days and does not require refrigeration. 

Note: For the specific urine container or further assistance, please contact Vettto.

Packing Instructions

Label each sample with the animal’s name and a unique identifier, using a permanent marker or a secure adhesive label. Ensure the submittal form is completed with the animal’s information and relevant medical history.

References

  1. Mochizuki, H.; Shapiro, S.G.; Breen, M. Detection of BRAF Mutation in Urine DNA as a Molecular Diagnostic for Canine Urothelial and Prostatic Carcinoma. PLoS ONE 2015, 10, e0144170. 
  2. Mochizuki H, Kennedy K, Shapiro SG, Breen M. BRAF Mutations in Canine Cancers. PLoS One. 2015 Jun 8;10(6):e0129534
  3. Aupperle-Lellbach, H., Kehl, A., de Brot, S. and van der Weyden, L., 2024. Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future. Veterinary sciences, 11(5), p.199.
  4. Grassinger, J.M., Merz, S., Aupperle-Lellbach, H., Erhard, H. and Klopfleisch, R., 2019. Correlation of BRAF variant V595E, breed, histological grade and cyclooxygenase-2 expression in canine transitional cell carcinomas. Veterinary sciences, 6(1), p.31.